DUBLIN, Calif.--(BUSINESS WIRE)-- SuperGen, Inc. (Nasdaq:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the acceptance of three ...
Homologous recombination repair gene mutation (HRRm) testing patterns and treatment selection from a real-world cohort of patients with metastatic castration-resistant prostate cancer (mCRPC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback